Ultragenyx and Kyowa Kirin Announce Crysvita Now Launched in the U.S. for the Treatment of X–linked Hypophosphatemia

Pharmaceutical Investing

Ultragenyx Pharmaceutical (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, Kyowa Hakko Kirin, and Kyowa Kirin International announced that Crysvita® (burosumab-twza) entered the commercial supply chain in the United States and generated its first sales to specialty pharmacies on April 27, 2018—ten days after its approval by …

Ultragenyx Pharmaceutical (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, Kyowa Hakko Kirin, and Kyowa Kirin International announced that Crysvita® (burosumab-twza) entered the commercial supply chain in the United States and generated its first sales to specialty pharmacies on April 27, 2018—ten days after its approval by the U.S. Food and Drug Administration (FDA).

As quoted in the press release:

Crysvita was approved by the FDA for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients one year of age and older. Crysvita is the first drug approved in the United States for XLH—a rare, hereditary, lifelong disease that affects approximately 12,000 people in the U.S.

“With this commercial launch of Crysvita, adults and children living with XLH now have access to the only treatment that targets the underlying cause of this debilitating disorder,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. “Our quick transition from approval to product availability demonstrates the urgency we feel about bringing Crysvita to patients. Through the UltraCare™ program, our next job is helping everyone who can benefit from Crysvita to navigate the health-care system and gain access to this new treatment.”

Dr. Tom Stratford, President and CEO of Kyowa Kirin International, said: “We are excited about the benefits Crysvita may bring to people affected by XLH and our U.S. team is looking forward to working alongside our colleagues at Ultragenyx to help make this important product a success.”

Click here to read the full press release.

The Conversation (0)
×